https://scholars.lib.ntu.edu.tw/handle/123456789/494899
標題: | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients | 作者: | BIN-CHI LIAO Griesing S. CHIH-HSIN YANG |
公開日期: | 2019 | 出版社: | SAGE Publications Inc. | 卷: | 11 | 來源出版物: | Therapeutic Advances in Medical Oncology | 摘要: | Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms of resistance following first- or second-generation EGFR-TKI therapy (e.g. gefitinib, erlotinib, afatinib, and dacomitinib). Patients without T790M are a heterogeneous group for whom platinum-based chemotherapy is currently recommended as a second-line treatment. In addition to secondary mutations in EGFR (e.g. T790M), the currently known resistance mechanisms can be classified into the following three categories: bypass pathways, downstream signaling pathways, and histologic transformations. Given the evolving knowledge and convenience of diagnosing acquired resistance mechanisms by next-generation sequencing and liquid biopsy, exploratory studies targeting these resistance mechanisms and incorporating immunotherapy into the treatment paradigm have become the mainstream of future development. This review focuses on acquired resistance mechanisms other than T790M that develop after first- or second-generation EGFR-TKI therapy. Exploratory second-line treatments targeting resistance mechanisms as well as combination immunotherapy and chemotherapy in ongoing clinical trials are reviewed here. We also highlight the recent development of next-generation sequencing and liquid biopsy in this field. ? The Author(s), 2019. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075623762&doi=10.1177%2f1758835919890286&partnerID=40&md5=9e6e25edd52c0b6d189317cbeed5be61 https://scholars.lib.ntu.edu.tw/handle/123456789/494899 |
ISSN: | 1758-8340 | DOI: | 10.1177/1758835919890286 | SDG/關鍵字: | afatinib; bemcentinib; buparlisib; capmatinib; crizotinib; dacomitinib; dubermatinib; emibetuzumab; epidermal growth factor receptor; epidermal growth factor receptor 2; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; kelch like ECH associated protein 1; luminespib; mammalian target of rapamycin; mitogen activated protein kinase; necitumumab; osimertinib; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; programmed death 1 ligand 1; protein tyrosine kinase; Raf protein; Ras protein; savolitinib; selumetinib; tepotinib; tivantinib; trastuzumab emtansine; unindexed drug; Akt signaling; Akt/mTOR signaling; cancer combination chemotherapy; cancer immunotherapy; cancer resistance; cancer staging; cell transformation; clinical trial (topic); decreased appetite; dermatitis; diarrhea; epithelial mesenchymal transition; fatigue; fever; fluorescence in situ hybridization; gene dosage; gene mutation; gene overexpression; human; hypoalbuminemia; immunohistochemistry; liquid biopsy; neutropenia; next generation sequencing; non small cell lung cancer; nonhuman; peripheral edema; Pi3K/Akt signaling; pneumonia; priority journal; progression free survival; Review; stomatitis; treatment duration; treatment response |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。